Literature DB >> 1939073

Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis.

C P Quinn1, Y Singh, K R Klimpel, S H Leppla.   

Abstract

Linker insertion mutagenesis was employed to create structural disruptions of the lethal factor (LF) protein of anthrax toxin to map functional domains. A dodecameric linker was inserted at 17 blunt end restriction enzyme sites throughout the gene. Paired MluI restriction sites within the linker allowed the inserts to be reduced from four to two amino acids. Shuttle vectors containing the mutated genes were transformed into the avirulent Bacillus anthracis UM23C1-1 for expression and secretion of the gene products. Mutations at five sites in the central one-third of the sequence made the protein unstable, and purified protein could not be obtained. Mutated LF proteins with insertions at the other sites were purified and assessed for toxic activity in a macrophage lysis assay and for their ability to bind to the protective antigen (PA) component of anthrax toxin, the receptor binding moiety. Most insertions located in the NH2-terminal one-third of the LF protein eliminated both toxicity and binding to PA, while all four insertions in the COOH-terminal one-third of the protein eliminated toxicity without affecting binding to PA. These data support the hypothesis that the NH2-terminal domain contains the structures required for binding to PA and the COOH-terminal domain contains the putative catalytic domain of LF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939073

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.

Authors:  Nam-Kyu Lim; Jung-Hwan Kim; Mee Sook Oh; Sangyoon Lee; Se-Yeon Kim; Keun-Soo Kim; Hyun-Jung Kang; Hyo Jeong Hong; Kyung-Soo Inn
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 2.  Membrane translocation by anthrax toxin.

Authors:  R John Collier
Journal:  Mol Aspects Med       Date:  2009-06-27

3.  Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis.

Authors:  F Brossier; M Weber-Levy; M Mock; J C Sirard
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Lethal factor active-site mutations affect catalytic activity in vitro.

Authors:  S E Hammond; P C Hanna
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

5.  A role for PACE4 in the proteolytic activation of anthrax toxin protective antigen.

Authors:  V M Gordon; A Rehemtulla; S H Leppla
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

Review 6.  Bacterial Virulence Factors: Secreted for Survival.

Authors:  Aditya Kumar Sharma; Neha Dhasmana; Neha Dubey; Nishant Kumar; Aakriti Gangwal; Meetu Gupta; Yogendra Singh
Journal:  Indian J Microbiol       Date:  2016-11-05       Impact factor: 2.461

Review 7.  Death at Sverdlovsk: what have we learned?

Authors:  D H Walker; O Yampolska; L M Grinberg
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

8.  Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells.

Authors:  N Arora; S H Leppla
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

9.  Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.

Authors:  Kristin H Clement; Thomas L Rudge; Heather J Mayfield; Lena A Carlton; Arelis Hester; Nancy A Niemuth; Carol L Sabourin; April M Brys; Conrad P Quinn
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

Review 10.  Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins.

Authors:  Holger Barth; Klaus Aktories; Michel R Popoff; Bradley G Stiles
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.